SEEL
Seelos Therapeutics, Inc.
Set alert
52-week range unavailable
- YTD
- -71.09%
- 1 year
- -71.09%
- Open
- 0.00
- Prev close
- 0.37
- Mkt cap
- 214.97K
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.37
- High
- 0.37
- Forward P/E
- -0.28
- Beta
- 1.94
- Short ratio
- 0.14
- Inst. own
- 41.09%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 19, 2024
- 50-d avg
- 1.87
- 200-d avg
- 29.73
- 1y target
- 0.00
Key statistics
- Market cap
- 214.97K
- Enterprise value
- 9.99M
- Trailing P/E
- 0.00
- Forward P/E
- -0.28
- PEG ratio
- 0.00
- Price / sales
- 0.11
- Price / book
- 0.00
- EPS (TTM)
- 351.04
- Beta
- 1.94
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 203.13%
- Revenue (TTM)
- 2.01M
- Revenue growth
- 11.90%
- Free cash flow
- -34.28M
- Total cash
- 294.00K
- Total debt
- 10.16M
- Return on equity
- 0.00%
- Shares outstanding
- 581.00K
- Short % of float
- 29.52%
- 50-day average
- 1.87
- 200-day average
- 29.73
Analyst view
Consensus: none
Next earnings
Nov 19, 2024
Expected Nov 19, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 19, 2024 | Sep 1, 2024 | 0.00 | — | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Mar 12, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Oct 6, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
About Seelos Therapeutics, Inc.
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therapy targeting gene and alpha synuclein; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; SLS-007, a peptidic inhibitor for NACore Parkinson disease; and SLS-009, a protein targeted autophagy for Alzheimer disease. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York. On November 16, 2024, Seelos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- seelostherapeutics.com
News
- "RFK Says Trump Administration Could Provide Psychedelic Therapy To Military Veterans 'Within 12 Months'" - Marijuana Moment
- 'Psychedelics Proponents Hope Trump Administration Will Foster A New Era' - STAT News
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- Crude Oil Gains Over 1%; BioVie Shares Plunge
- Nasdaq Surges 100 Points; Thor Industries Earnings Top Views
- Dow Rises Over 50 Points; AutoZone Posts Downbeat Earnings
- Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- Why Greenland Technologies Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- 12 Health Care Stocks Moving In Monday's After-Market Session
Your note
Sign in to keep a note on SEEL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GOLEMBIEWSKI MICHAEL JOSEPH | Chief Financial Officer | Stock Award(Grant) | Feb 28, 2024 | 86,869 |
| MEHRA RAJ | Chief Executive Officer | Purchase | Nov 30, 2023 | 185,142 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AdvisorShares Investments, LLC | 1.61% | 18,113 | 6.70K | Sep 29, 2024 |
| Modera Wealth Management, LLC | 0.96% | 10,805 | 4.00K | Sep 29, 2024 |
| UBS Group AG | 0.75% | 8,477 | 3.14K | Sep 29, 2024 |
| Morgan Stanley | 0.06% | 675 | 249 | Sep 29, 2024 |
| Blackrock Inc. | 0.03% | 354 | 130 | Sep 29, 2024 |
| Carmichael Hill & Associates, Inc. | 0.01% | 62 | 22 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 1.61% | 18,113 | 6.70K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.18% | 2,054 | 759 | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.04% | 437 | 161 | Jun 29, 2024 |
| Fidelity Total Market Index Fund | 0.00% | 51 | 18 | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.00% | 41 | 15 | Sep 29, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.00% | 22 | 8 | Sep 29, 2024 |